Bazedoxifene–Conjugated Estrogens for Treating Endometriosis

Valerie A Flores, Nina S Stachenfeld, Hugh S Taylor
Obstetrics and gynecology · 2018 · vol. 132(2) , pp. 475–477 · doi:10.1097/aog.0000000000002739 · PMID:29995747 · W2845089368
article OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

A patient with stage III endometriosis experienced resolution of pelvic pain and no adverse effects when treated with bazedoxifene and conjugated estrogens for over six months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Endometriosis is a gynecologic disorder affecting 6-10% of reproductive-aged women. First-line therapies are progestin-based regimens; however, failure rates are high, often requiring alternative hormonal agents, each with unfavorable side effects. Bazedoxifene with conjugated estrogens is approved for treatment of menopausal symptoms, and use in animal studies has demonstrated regression of endometriotic lesions. As such, it represents a potential treatment option for endometriosis. CASE: A patient with stage III endometriosis referred for management of dysmenorrhea and cyclic pelvic pain was treated with 20 mg bazedoxifene and 0.45 mg conjugated estrogens daily for more than 6 months. She noted resolution of pelvic pain. There were no abnormal effects on hormonal, uterine, or ovarian parameters. CONCLUSION: Bazedoxifene with conjugated estrogens may be an effective alternative to traditional endometriosis treatment options.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosisdysmenorrhea

MeSH descriptors

Endometriosis Estrogens Estrogens, Conjugated (USP) Indoles Selective Estrogen Receptor Modulators Adult Drug Therapy, Combination Endometriosis Estrogens Estrogens, Conjugated (USP) Female Humans Indoles Selective Estrogen Receptor Modulators

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (19)

Cited by (6)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:19:43.094626+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK